AR092223A1 - Derivados biciclicos de piridina - Google Patents
Derivados biciclicos de piridinaInfo
- Publication number
- AR092223A1 AR092223A1 ARP130103005A ARP130103005A AR092223A1 AR 092223 A1 AR092223 A1 AR 092223A1 AR P130103005 A ARP130103005 A AR P130103005A AR P130103005 A ARP130103005 A AR P130103005A AR 092223 A1 AR092223 A1 AR 092223A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- alkyl
- cycloalkyl
- haloalkyl
- cycloalkoxyalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
Composiciones que incluyen los compuestos y métodos de uso de los compuestos. Reivindicación 1: Compuestos de la fórmula (1) en la que R¹ es alquilo, haloalquilo, cicloalquilo, cicloalquilo sustituido, alcoxi, alcoxialquilo, alcoxialcoxi, alcoxicarbonilo, alcoxicarbonilalquilo, carboxi, carboxialquilo, haloalquilo, haloalcoxi, haloalcoxialquilo, cicloalcoxi, cicloalcoxi sustituido, cicloalcoxilalquilo, cicloalcoxialquilo sustituido, hidroxialquilo, arilo, arilo sustituido, heterocicloalquilo, heterocicloalquilo sustituido, heterocicloalcoxi, heterocicloalcoxi sustituido, heterocicloalquilalcoxi, heterocicloalquilalcoxi sustituido, heteroarilo, heteroarilo sustituido, amino, amino sustituido, aminocarbonilo o aminocarbonilo sustituido, dichos cicloalquilo sustituido, cicloalcoxi sustituido, cicloalcoxialquilo sustituido, arilo sustituido, heterocicloalquilo sustituido, heterocicloalcoxi sustituido, heterocicloalquilalcoxi sustituido y heteroarilo sustituido están sustituidos de una a tres veces por sustituyentes elegidos con independencia entre hidroxi, oxo, halógeno, alquilo, cicloalquilo, haloalquilo, alquilcicloalquilo, cicloalquilalquilo, alquilcicloalquilalquilo, hidroxialquilo, alquilsulfonilo, alquilsulfonilalquilo, alcoxicarbonilo, alcoxi y alcoxialquilo y dichos amino sustituido y aminocarbonilo sustituido están sustituidos sobre el átomo de nitrógeno por uno o dos sustituyentes elegidos con independencia entre alquilo, cicloalquilo, haloalquilo, alquilcicloalquilo, cicloalquilalquilo, alquilcicloalquilalquilo, hidroxialquilo y alcoxialquilo; R² es -COOH, tetrazol-5-ilo, [1,3,4]oxadiazol-2-on-5-ilo, [1,3,4]oxadiazol-2-tion-5-ilo, [1,2,4]oxadiazol-5-on-3-ilo, [1,2,4]oxadiazol-5-tion-3-ilo, [1,2,3,5]oxatiadiazol-2-óxido-4-ilo, [1,2,4]tiadiazol-5-on-3-ilo, isoxazol-3-ol-5-ilo, 5-alquilisoxazol-3-ol-4-ilo, 5-cicloalquilisoxazol-3-ol-4-ilo, furazan-3-ol-4-ilo, 5-alquilsulfonilamino-[1,3,4]oxadiazol-2-ilo, 5-cicloalquil-sulfonilamino-[1,3,4]oxadiazol-2-ilo, 5-alquilsulfonilamino-[1,2,4]triazol-3-ilo, 5-cicloalquil-sulfonilamino-[1,2,4]triazol-3-ilo, 5-alquilisotiazol-3-ol-4-ilo, 5-cicloalquilisotiazol-3-ol-4-ilo, [1,2,5]tiadiazol-3-ol-4-ilo, 1,4-dihidro-tetrazol-5-on-1-ilo, tetrazol-5-il-carbamoilo, tetrazol-5-carbonilo, [1,2,4]oxadiazolidina-3,5-dion-2-ilo, [1,2,4]oxadiazol-5-on-3-ilo, 2,4-dihidro-[1,2,4]-triazol-3-ilo-on-5-sulfanilo, [1,2,4]triazol-3-sulfanilo, [1,2,4]triazol-3-sulfinilo, [1,2,4]triazol-3-sulfonilo, 4-alquil-pirazol-1-ol-5-ilo, 4-cicloalquil-pirazol-1-ol-5-ilo, 4-alquil-[1,2,3]triazol-1-ol-5-ilo, 4-cicloalquil-[1,2,3]triazol-1-ol-5-ilo, 5-alquil-imidazol-1-ol-2-ilo, 5-cicloalquil-imidazol-1-ol-2-ilo, 4-alquil-imidazol-1-ol-5-ilo, 4-cicloalquil-imidazol-1-ol-5-ilo, 4-alquil-1,1-dioxo-1l⁶-[1,2,5]-tiadiazolidin-3-on-5-ilo, 4,4-dialquil-1,1-dioxo-1l⁶-[1,2,5]-tiadiazolidin-3-on-5-ilo, 4-cicloalquil-1,1-dioxo-1l⁶-[1,2,5]tiadiazolidin-3-on-5-ilo, 4,4-dialquil-1,1-dioxo-1l⁶-[1,2,5]tiadiazolidin-3-on-5-ilo, tiazolidina-2,4-dion-5-ilo, oxazolidina-2,4-dion-5-ilo, 3-[1-hidroxi-met-(E)-ilideno]-pirrolidina-2,4-dion-1-ilo, 3-[1-hidroxi-met-(Z)-ilideno]-pirrolidina-2,4-dion-1-ilo, 5-metil-4-hidroxifuran-2-on-3-ilo, 5,5-dialquil-4-hidroxifuran-2-on-3-ilo, 5-cicloalquil-4-hidroxifuran-2-on-3-ilo, 5,5-dicicloalquil-4-hidroxifuran-2-on-3-ilo, 3-hidroxiciclobut-3-eno-1,2-dion-4-ilo o 3-hidroxiciclobut-3-eno-1,2-dion-4-amino; R³ es fenilo, fenilo sustituido, dihidropiridinilo sustituido, heteroarilo o heteroarilo sustituido, dichos fenilo sustituido, dihidropiridinilo sustituido y heteroarilo sustituido están sustituidos de una a tres veces por sustituyentes elegidos con independencia entre hidroxi, oxo, halógeno, alquilo, cicloalquilo, haloalquilo, haloalcoxi, alquilcicloalquilo, cicloalquilalquilo, alquilcicloalquilalquilo, hidroxialquilo, hidroxialcoxi, alcoxi, alcoxialquilo, alquilsulfonilo, amino y amino sustituido sobre el átomo de nitrógeno por uno o dos sustituyentes elegidos con independencia entre alquilo, cicloalquilo, haloalquilo, alquilcicloalquilo, cicloalquilalquilo, alquilcicloalquilalquilo, hidroxialquilo y alcoxialquilo; A¹ es un enlace o CR¹²R¹³; A² es -CR¹⁴R¹⁵-, -NR¹⁶-, -O-, -S-, -S(O)- o -S(O)₂-; A³ es -CR¹⁷R¹⁸-, -C(O)NR¹⁹-, -NR¹⁹-, -O-, -S-, -S(O)- o -S(O)₂-; R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹⁴, R¹⁵, R¹⁷ y R¹⁸ se eligen con independencia entre H, halógeno, alquilo, alcoxi, cicloalquilo, cicloalquilalcoxi, haloalcoxi y haloalquilo; R¹² y R¹³ se eligen con independencia entre hidrógeno, alquilo, cicloalquilo y haloalquilo; R¹⁶ y R¹⁹ se eligen con independencia entre hidrógeno, alquilo, cicloalquilo, haloalquilo y alquilcarbonilo; n, m y p se eligen con independencia entre cero y 1; o sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12181739 | 2012-08-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR092223A1 true AR092223A1 (es) | 2015-04-08 |
Family
ID=46851316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130103005A AR092223A1 (es) | 2012-08-24 | 2013-08-26 | Derivados biciclicos de piridina |
Country Status (14)
Country | Link |
---|---|
US (1) | US9562052B2 (es) |
EP (1) | EP2888245B1 (es) |
JP (1) | JP6258937B2 (es) |
KR (1) | KR20150046056A (es) |
CN (1) | CN104583197B (es) |
AR (1) | AR092223A1 (es) |
BR (1) | BR112015002950A2 (es) |
CA (1) | CA2873295A1 (es) |
ES (1) | ES2596243T3 (es) |
HK (1) | HK1205508A1 (es) |
MX (1) | MX2015001099A (es) |
RU (1) | RU2648247C2 (es) |
TW (1) | TWI614237B (es) |
WO (1) | WO2014029723A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
EP3418281B1 (en) | 2012-12-07 | 2020-09-30 | Vertex Pharmaceuticals Inc. | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of atr kinase for the treatment of cancer diseases |
EP2970289A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
WO2014143242A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2970286A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
MX370390B (es) | 2013-12-06 | 2019-12-11 | Vertex Pharma | Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados. |
CN110590787A (zh) | 2014-06-05 | 2019-12-20 | 沃泰克斯药物股份有限公司 | Atr激酶抑制剂的制备方法及其不同的固体形式 |
JP6936007B2 (ja) | 2014-06-17 | 2021-09-15 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Chk1阻害剤とatr阻害剤との組み合わせを使用してがんを処置する方法 |
MX2018003657A (es) | 2015-09-30 | 2018-04-30 | Vertex Pharma | Metodo para tratar cancer usando una combinacion de agentes que dañan el adn e inhibidores de proteina relacionada con ataxia telangiectasia y rad3 (atr). |
CN107556309B (zh) * | 2017-09-11 | 2020-12-01 | 浙江永宁药业股份有限公司 | 多取代四氢萘啶类化合物的药物用途及其制备方法 |
CN107540672A (zh) * | 2017-10-10 | 2018-01-05 | 牡丹江医学院 | 一种治疗肝硬化的药物及其合成方法 |
CN114907372B (zh) * | 2022-04-26 | 2023-07-04 | 黑龙江中医药大学 | 一种用于治疗多囊卵巢综合征的药物及其制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW232013B (es) * | 1992-04-24 | 1994-10-11 | Takeda Pharm Industry Co Ltd | |
NO306992B1 (no) * | 1993-01-28 | 2000-01-24 | Takeda Chemical Industries Ltd | Quinolinderivater, farmasoeytiske preparater inneholdende forbindelsene og anvendelsen av forbindelsene |
DE69422450T2 (de) * | 1993-06-29 | 2000-06-08 | Takeda Chemical Industries Ltd | Chinoline oder Chinazolin-Derivate und deren Verwendung zur Herstellung eines Medikaments für die Behandlung von Osteoporose |
AR008789A1 (es) * | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
TW477787B (en) * | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
DE19741399A1 (de) * | 1997-09-19 | 1999-03-25 | Bayer Ag | Tetrahydrochinoline |
JP4473698B2 (ja) * | 2003-10-31 | 2010-06-02 | 武田薬品工業株式会社 | ピリジン化合物 |
US7521557B2 (en) * | 2005-05-20 | 2009-04-21 | Bristol-Myers Squibb Company | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods |
JO3077B1 (ar) * | 2005-07-28 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينولين مضادة للبكتيريا |
US7994321B2 (en) * | 2006-08-08 | 2011-08-09 | Hoffmann-La Roche Inc. | Substituted thieno[3,2-C]pyridine-7-carboxylic acid derivatives |
WO2008064107A2 (en) * | 2006-11-20 | 2008-05-29 | Bristol-Myers Squibb Company | 7,8-dihydro-1,6-naphthyridin-5(6h)-ones and related bicyclic compounds as inhibitors of dipeptidyl peptidase iv and methods |
CN101245062A (zh) * | 2007-02-16 | 2008-08-20 | 中国科学院上海药物研究所 | 四氢喹啉类化合物、其制备方法及药物组合物 |
US8815875B2 (en) * | 2008-11-12 | 2014-08-26 | Merck Sharp & Dohme Corp. | Inhibitors of fatty acid binding protein (FABP) |
US8889683B2 (en) * | 2010-09-27 | 2014-11-18 | Merck Sharp & Dohme Corp. | Substituted quinoxalines as inhibitors of fatty acid binding protein |
KR20140088194A (ko) * | 2011-11-04 | 2014-07-09 | 에프. 호프만-라 로슈 아게 | 아릴-퀴놀린 유도체 |
-
2013
- 2013-08-19 ES ES13750576.4T patent/ES2596243T3/es active Active
- 2013-08-19 BR BR112015002950A patent/BR112015002950A2/pt not_active Application Discontinuation
- 2013-08-19 JP JP2015527878A patent/JP6258937B2/ja not_active Expired - Fee Related
- 2013-08-19 MX MX2015001099A patent/MX2015001099A/es unknown
- 2013-08-19 KR KR1020157004693A patent/KR20150046056A/ko active IP Right Grant
- 2013-08-19 CA CA2873295A patent/CA2873295A1/en not_active Abandoned
- 2013-08-19 WO PCT/EP2013/067220 patent/WO2014029723A1/en active Application Filing
- 2013-08-19 CN CN201380043454.0A patent/CN104583197B/zh not_active Expired - Fee Related
- 2013-08-19 RU RU2015107979A patent/RU2648247C2/ru not_active IP Right Cessation
- 2013-08-19 EP EP13750576.4A patent/EP2888245B1/en not_active Not-in-force
- 2013-08-23 TW TW102130340A patent/TWI614237B/zh not_active IP Right Cessation
- 2013-08-26 AR ARP130103005A patent/AR092223A1/es unknown
-
2015
- 2015-02-20 US US14/627,358 patent/US9562052B2/en not_active Expired - Fee Related
- 2015-06-25 HK HK15106063.2A patent/HK1205508A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
BR112015002950A2 (pt) | 2017-08-08 |
CN104583197A (zh) | 2015-04-29 |
ES2596243T3 (es) | 2017-01-05 |
HK1205508A1 (en) | 2015-12-18 |
JP6258937B2 (ja) | 2018-01-10 |
WO2014029723A1 (en) | 2014-02-27 |
JP2015526452A (ja) | 2015-09-10 |
CA2873295A1 (en) | 2014-02-27 |
TW201414720A (zh) | 2014-04-16 |
RU2648247C2 (ru) | 2018-03-23 |
TWI614237B (zh) | 2018-02-11 |
US9562052B2 (en) | 2017-02-07 |
EP2888245B1 (en) | 2016-09-21 |
RU2015107979A (ru) | 2016-10-20 |
KR20150046056A (ko) | 2015-04-29 |
US20150368256A1 (en) | 2015-12-24 |
CN104583197B (zh) | 2017-05-17 |
MX2015001099A (es) | 2015-04-08 |
EP2888245A1 (en) | 2015-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR092223A1 (es) | Derivados biciclicos de piridina | |
AR104208A1 (es) | Compuestos bicíclicos como inhibidores de autotaxina (atx) | |
AR087901A1 (es) | Derivados dihidroquinolina-2-ona como inhibidores de la aldosterona sintasa y procedimiento para su obtencion | |
AR088625A1 (es) | Derivados de aril-quinolina | |
AR103969A1 (es) | Inmunomoduladores | |
AR091279A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
AR095706A1 (es) | Indazoles sustituidos con heteroarilo | |
AR087711A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y uso de los mismos para el tratamiento de trastornos neurodegenerativos | |
AR103182A1 (es) | Inmunomoduladores | |
CO6160237A2 (es) | Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden | |
AR087984A1 (es) | Derivados biciclicos de dihidroquinolina-2-ona | |
AR097571A1 (es) | Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa | |
AR099823A1 (es) | Compuestos bicíclicos de 7 eslabones | |
AR091257A1 (es) | Derivados de bencimidazol-prolina | |
AR087809A1 (es) | Benzo[b]tiofen-4-il-piperazino sustituidos, su uso en el tratamiento de enfermedades psicoticas y un metodo para su preparacion | |
AR093805A1 (es) | Derivados de piridina agonistas del receptor 2 de cannabinoides | |
AR070463A1 (es) | Compuestos de amina y eter que modulan el receptor cb2 | |
AR095079A1 (es) | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo | |
AR057626A1 (es) | Derivados de pirido pirazo y pirimido- pirimidina y su uso como inhibidores de mtor | |
AR079334A1 (es) | Derivados de oxazin amino | |
AR090037A1 (es) | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio | |
AR067327A1 (es) | Derivados de piperidina / piperazina | |
AR095570A1 (es) | Derivados de urea | |
AR084913A1 (es) | Derivados de aril-benzocicloalquil-amida | |
AR090678A1 (es) | Derivados de fenil-tetrahidroisoquinolina como inhibidores de la aldosterona-sintasa y un metodo para su sintesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |